HUP0500846A2 - Pharmaceutical formulation with an insoluble active agent for pulmonary administration - Google Patents

Pharmaceutical formulation with an insoluble active agent for pulmonary administration

Info

Publication number
HUP0500846A2
HUP0500846A2 HU0500846A HUP0500846A HUP0500846A2 HU P0500846 A2 HUP0500846 A2 HU P0500846A2 HU 0500846 A HU0500846 A HU 0500846A HU P0500846 A HUP0500846 A HU P0500846A HU P0500846 A2 HUP0500846 A2 HU P0500846A2
Authority
HU
Hungary
Prior art keywords
active agent
pharmaceutical formulation
pulmonary administration
insoluble active
insoluble
Prior art date
Application number
HU0500846A
Other languages
English (en)
Inventor
Thomas E Tarara
Jeffry G Weers
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32713146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0500846(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of HUP0500846A2 publication Critical patent/HUP0500846A2/hu
Publication of HUP0500846A3 publication Critical patent/HUP0500846A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU0500846A 2002-12-31 2003-12-31 Pharmaceutical formulation with an insoluble active agent for pulmonary administration HUP0500846A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43721002P 2002-12-31 2002-12-31
PCT/US2003/041703 WO2004060351A2 (en) 2002-12-31 2003-12-31 Pharmaceutical formulation with an insoluble active agent for pulmonary administration

Publications (2)

Publication Number Publication Date
HUP0500846A2 true HUP0500846A2 (en) 2008-05-28
HUP0500846A3 HUP0500846A3 (en) 2008-10-28

Family

ID=32713146

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500846A HUP0500846A3 (en) 2002-12-31 2003-12-31 Pharmaceutical formulation with an insoluble active agent for pulmonary administration

Country Status (18)

Country Link
US (1) US20040156792A1 (hu)
EP (1) EP1589947B2 (hu)
JP (1) JP2006513236A (hu)
KR (1) KR20050095838A (hu)
CN (1) CN1741789A (hu)
AU (1) AU2003300137A1 (hu)
BR (1) BR0317810A (hu)
CA (1) CA2511523C (hu)
EA (1) EA200501001A1 (hu)
ES (1) ES2589578T5 (hu)
HU (1) HUP0500846A3 (hu)
MX (1) MXPA05007158A (hu)
NO (1) NO20053076L (hu)
PL (1) PL378270A1 (hu)
PT (1) PT1589947T (hu)
TR (1) TR200502522T2 (hu)
WO (1) WO2004060351A2 (hu)
ZA (1) ZA200505155B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
CA2468958C (en) * 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
TW200503781A (en) * 2002-12-31 2005-02-01 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
EP1635786A2 (en) 2003-05-28 2006-03-22 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
US8513204B2 (en) * 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
CA2623256A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Receptacles and kits, such as for dry powder packaging
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20120128728A1 (en) * 2005-12-28 2012-05-24 Novartis Pharma Ag Compositions Comprising Amphotericin B
EP1986679B1 (en) * 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
DE102006053375A1 (de) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
UA97286C2 (ru) * 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
PL220269B1 (pl) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
MX2010012452A (es) * 2008-05-15 2011-03-15 Novartis Ag Star Suministro pulmonar de una fluoro-quinolona.
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US9724664B2 (en) 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
JP2013540827A (ja) * 2010-10-29 2013-11-07 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ 三種混合製剤
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
WO2015117069A1 (en) * 2014-02-03 2015-08-06 The Board Of Trustees Of The Leland Stanford Junior University Formulations for microparticle delivery of zinc protoporphyrins
EP3212169B1 (en) 2014-10-31 2021-01-13 Bend Research, Inc. Process for forming active domains dispersed in a matrix
CN104587457B (zh) * 2015-01-13 2017-03-22 广东海大畜牧兽医研究院有限公司 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
ES2948157T3 (es) * 2015-12-24 2023-09-01 Philip Morris Products Sa Cápsula de partículas de nicotina
KR20180102201A (ko) 2016-02-01 2018-09-14 인카다 테라퓨틱스, 인크. 심방 세동을 포함한 심장 부정맥을 관리하기 위한 전자 모니터링과 흡입 약리 치료의 조합
WO2018209107A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2019003118A1 (en) * 2017-06-28 2019-01-03 Philip Morris Products S.A. CONTAINER WITH PARTICLES FOR USE WITH INHALER
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
GB201817865D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437210A (en) 1890-09-30 Electric street-car
SE408265B (sv) * 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) * 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) * 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) * 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
DE69233690T2 (de) * 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP3388896B2 (ja) * 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
CA2218074C (en) * 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
EP1019020A1 (en) * 1997-09-29 2000-07-19 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
WO2000001365A1 (en) 1998-06-30 2000-01-13 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Prolonged release ophthalmic compositions containing a fluoroquinolone
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US6357490B1 (en) * 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
CA2432319A1 (en) 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents

Also Published As

Publication number Publication date
PL378270A1 (pl) 2006-03-20
CA2511523C (en) 2013-10-15
NO20053076D0 (no) 2005-06-23
CN1741789A (zh) 2006-03-01
BR0317810A (pt) 2005-11-29
JP2006513236A (ja) 2006-04-20
NO20053076L (no) 2005-09-13
EP1589947B8 (en) 2016-08-24
ES2589578T3 (es) 2016-11-15
US20040156792A1 (en) 2004-08-12
EP1589947A2 (en) 2005-11-02
MXPA05007158A (es) 2005-09-21
WO2004060351A2 (en) 2004-07-22
EP1589947B2 (en) 2019-01-30
EA200501001A1 (ru) 2005-12-29
AU2003300137A1 (en) 2004-07-29
ES2589578T5 (es) 2019-07-23
KR20050095838A (ko) 2005-10-04
PT1589947T (pt) 2016-09-05
EP1589947B1 (en) 2016-06-15
HUP0500846A3 (en) 2008-10-28
CA2511523A1 (en) 2004-07-22
ZA200505155B (en) 2006-04-26
WO2004060351A3 (en) 2004-09-30
TR200502522T2 (tr) 2005-09-21

Similar Documents

Publication Publication Date Title
HUP0500846A2 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
AP2005003318A0 (en) Pharmaceutical compositions comprising a basic respectively acidic drug coumpound, a surfactant and a physiologically tolerable watersoluble acid respectively base.
PL351526A1 (en) Pharmaceutical formulation comprising amoxycillin
DK1545467T3 (da) Faste farmaceutiske formuleringer omfattende telmisartan
AU2003282782A8 (en) Pharmaceutically active lipid based formulation of sn38
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
IL172619A0 (en) Pharmaceutical formulation comprising levothyroxine sodium
TWI319317B (en) Modified release pharmaceutical formulation
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
CL2004000564A1 (es) Formulacion farmaceutica para administracion oral que comprende uno o mas agentes farmaceuticamente activos y cacao en polvo.
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
IL165069A0 (en) Immediate release pharmaceutical formulation
AU2003280387A1 (en) Pharmaceutical formulation comprising azithrocycin monohydrate
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
GB2410187B (en) Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines
GB0201607D0 (en) Formulation for the administration of medicinal substances
AU2003229656A1 (en) A pharmaceutical formulation for endonasal administration and its use in the treatment of rhinitic symptoms
AU2003238900A8 (en) Pharmaceutical formulation
AU2001287930A1 (en) Pharmaceutical formulation for pulmonary or nasal administration
GB0225041D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees